靶向Aurora激酶A预防清髓性异基因造血细胞移植后GVHD与复发
该1期剂量探索试验在清髓性异基因造血细胞移植后联合使用PTCy、西罗莫司和口服选择性AURKA抑制剂VIC-1911。最佳剂量为75 mg每日两次,可有效抑制AURKA活性,180天内无3-4级急性GVHD,1年中重度慢性GVHD和复发率低,1年总生存率94%。
要点
- VIC-1911联合PTCy和西罗莫司方案耐受良好,最佳剂量为75 mg每日两次。
- 180天内无3-4级急性GVHD发生,1年中重度慢性GVHD发生率为6%。
- 1年复发率为0%,1年总生存率达94%。
核心结论
- VIC-1911 75 mg每日两次联合PTCy和西罗莫司可有效抑制AURKA活性,在清髓性allo-HCT后提供有希望的GVHD和复发预防,安全性良好且早期临床结局积极。
研究设计与样本
- 1期剂量探索试验,纳入18至60岁接受清髓性预处理的患者,给予PTCy(50 mg/kg;+3/+4天)、西罗莫司(+5天起;目标8-12 ng/mL)和VIC-1911(25、50或75 mg每日两次;+5至+45天)。
- 主要终点为第+21天CD4+ T细胞中磷酸化组蛋白H3丝氨酸10表达<54%。
- 小鼠和体外研究为该新型药物组合的开发提供了依据。
- 试验注册号NCT05120570。
主要发现
- 达到目标通路抑制且无剂量限制性毒性的最佳VIC-1911剂量为75 mg每日两次。
- 截至第180天无3-4级急性GVHD发生(0%)。
- 截至1年,中重度慢性GVHD发生率为6%,复发率为0%(5/16接受了维持治疗)。
- 该队列1年总生存率为94%。
- 临床前模型显示西罗莫司联合AURKA抑制可抑制CD28下游信号,增强GVHD预防并利用AURKA抑制的抗白血病活性。
临床怎么用
- 在清髓性allo-HCT后,可考虑PTCy联合西罗莫司及VIC-1911 75 mg每日两次(+5至+45天)作为GVHD和复发预防的候选方案。
- 西罗莫司目标血药浓度为8-12 ng/mL。
- 需监测AURKA通路抑制效果(CD4+ T细胞p-H3S10<54%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The success of posttransplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis has driven efforts to optimize partner therapies that balance GVHD and relapse prevention. We report phase 1 dose-finding results of PTCy, sirolimus (SIR), and VIC-1911, a selective oral Aurora kinase A (AURKA) inhibitor, after myeloablative allogeneic hematopoietic cell transplantation (allo-HCT). Results from murine and in vitro studies informed the development of the novel drug combination. In the phase 1 trial, patients aged 18 to 60 years received myeloablative conditioning, followed by PTCy (50 mg/kg; days +3/+4), SIR (from day +5; target 8-12 ng/mL), and VIC-1911 (25, 50, or 75 mg twice daily; days +5 to +45). The primary end point was achieving <54% phosphorylated histone H3 serine 10 expression in CD4+ T cells by day +21. Preclinical models show that combining SIR with AURKA inhibition suppresses signaling downstream of CD28, enhancing GVHD prevention while leveraging the antileukemia activity of AURKA inhibition. In the phase 1 trial, the optimal VIC-1911 dose achieving target pathway inhibition without dose-limiting toxicities was 75 mg twice daily. Clinical outcomes included no grade 3 to 4 acute GVHD through day 180 (0%) and low rates of moderate/severe chronic GVHD (6%) and relapse (0%) through 1 year (5/16 received maintenance). The 1-year overall survival for this cohort was 94%. VIC-1911 at 75 mg twice daily, combined with PTCy and SIR, effectively suppressed AURKA activity, offering promising GVHD and relapse prevention with a favorable safety profile and promising early clinical outcomes. The trial was registered at www.clinicaltrials.gov as NCT05120570.
引用
- Holtan SG, Grover P, Walton K, et al. Targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation. Blood Adv. 2026. PMID: 41592279. doi:10.1182/bloodadvances.2025017360
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。